Amylin Pharmaceuticals (Nasdaq: AMLN) and Japan’s Takeda Pharmaceutical (TSE: 4502) are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity, a Phase II trial of which was halted earlier this year (The Pharma Letter March 17).
The joint decision was based on a commercial reassessment of the pramlintide/metreleptin program, which had been in Phase II development as a twice-a-day injection formulation. The commercial assessment took into account a revised development plan as well as evolving dynamics within the obesity therapeutic area. The companies will continue to evaluate other assets as potential candidates for the treatment of obesity and related indications under the terms of their existing collaboration agreement.
Takeda acquired co-development rights to the combination obesity drug with an upfront payment of $75 million and worth a potential $1 billion to Amylin (TPL November 2, 2009).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze